Who is eligible for clinical trial NCT06291376?

Participants must meet protocol criteria for Immunoglobulin A Nephropathy. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06291376 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-17

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (NCT06291376)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Alexion Pharmaceuticals, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

Who can join: Review the eligibility criteria below.

Location: Research Site — Alabaster, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (246 Sites)

Showing the first 25 of 246 sites.

Research Site — Alabaster, Alabama
Research Site — Phoenix, Arizona
Research Site — Los Angeles, California
Research Site — Los Angeles, California
Research Site — Los Angeles, California
Research Site — Orange, California
Research Site — San Bernardino, California
Research Site — San Diego, California
Research Site — San Francisco, California
Research Site — Stanford, California
Research Site — Torrance, California
Research Site — Valencia, California
Research Site — Bay Pines, Florida
Research Site — Miami, Florida
Research Site — Orlando, Florida
Research Site — Acworth, Georgia
Research Site — Atlanta, Georgia
Research Site — Lawrenceville, Georgia
Research Site — New Orleans, Louisiana
Research Site — Boston, Massachusetts
Research Site — Boston, Massachusetts
Research Site — Boston, Massachusetts
Research Site — Worcester, Massachusetts
Research Site — Minneapolis, Minnesota
Research Site — Minneapolis, Minnesota

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Immunoglobulin A Nephropathy

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) — Birmingham, Alabama
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — Huntsville, Alabama
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy — Birmingham, Alabama
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US — Boston, Massachusetts

Explore by condition: All Immunoglobulin A Nephropathy clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗